Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression

NCT01034917 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

HIV

Interventions

DRUG: Etravirine 400 mg dissolved in water every 24 hours
DRUG: Continue with the same antiretroviral regimen

Sponsor

Germans Trias i Pujol Hospital